Augmentin (ES)-600 — Competitive Intelligence Brief

Augmentin (ES)-600 (Augmentin (ES)-600) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Beta-lactam antibiotic with beta-lactamase inhibitor. Area: Infectious Disease.

marketed Beta-lactam antibiotic with beta-lactamase inhibitor Penicillin-binding proteins (PBPs); bacterial beta-lactamase Infectious Disease Small molecule

Target snapshot

Augmentin (ES)-600 (Augmentin (ES)-600) — GlaxoSmithKline. Augmentin ES-600 is a combination antibiotic that inhibits bacterial cell wall synthesis by blocking penicillin-binding proteins, with enhanced coverage against beta-lactamase-producing organisms.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Augmentin (ES)-600 TARGET	Augmentin (ES)-600	GlaxoSmithKline	marketed	Beta-lactam antibiotic with beta-lactamase inhibitor	Penicillin-binding proteins (PBPs); bacterial beta-lactamase
Amoxicillin potassium clavulanate	Amoxicillin potassium clavulanate	Kaizen Bioscience Co.	marketed	Beta-lactam antibiotic with beta-lactamase inhibitor	Penicillin-binding proteins (PBPs); bacterial beta-lactamases
Imipenem+Relebactam	Imipenem+Relebactam	Wake Forest University Health Sciences	marketed	Beta-lactam antibiotic with beta-lactamase inhibitor	Penicillin-binding proteins (imipenem); serine beta-lactamases (relebactam)
Amoxicillin clavulanic	Amoxicillin clavulanic	Hospital Italiano de Buenos Aires	marketed	Beta-lactam antibiotic with beta-lactamase inhibitor	Penicillin-binding proteins (PBPs); bacterial beta-lactamases
standard dose amoxicillin/clavulanate	standard dose amoxicillin/clavulanate	Albany Medical College	marketed	Beta-lactam antibiotic with beta-lactamase inhibitor	Penicillin-binding proteins (PBPs); bacterial beta-lactamase
Augmentin®	Augmentin®	Teva Pharmaceuticals USA	marketed	Beta-lactam antibiotic with beta-lactamase inhibitor	Bacterial penicillin-binding proteins (PBPs); beta-lactamase enzymes
Amoxicillin-Potassium Clavulanate Combination	Amoxicillin-Potassium Clavulanate Combination	Universidad Complutense de Madrid	marketed	Beta-lactam antibiotic with beta-lactamase inhibitor	Penicillin-binding proteins (PBPs); bacterial beta-lactamases

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Beta-lactam antibiotic with beta-lactamase inhibitor class)

1. Medical University of Vienna · 2 drugs in this class
2. GlaxoSmithKline · 2 drugs in this class
3. Phoenix Children's Hospital · 2 drugs in this class
4. Albany Medical College · 2 drugs in this class
5. Pfizer · 2 drugs in this class
6. Imperial College London · 1 drug in this class
7. Hospital Italiano de Buenos Aires · 1 drug in this class
8. Bayer · 1 drug in this class
9. Maggiore Bellaria Hospital, Bologna · 1 drug in this class
10. Kaizen Bioscience Co. · 1 drug in this class